| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $333,689 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Moore David Scott | director | 1 | $250,236 | 0 | $0 | $250,236 |
| MILLER RICHARD A MD | President and CEO | 1 | $83,453 | 0 | $0 | $83,453 |
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling …
Over the last 12 months, insiders at Corvus Pharmaceuticals, Inc. have bought $333,689 and sold $0 worth of Corvus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Corvus Pharmaceuticals, Inc. have bought $385,086 and sold $9.78M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Moore David Scott (director) — $250,236. MILLER RICHARD A MD (President and CEO) — $83,453.
The last purchase of 21,700 shares for transaction amount of $250,236 was made by Moore David Scott (director) on 2026‑06‑11.
| 2026-06-11 | Moore David Scott | director | 21,700 0.0257% | $11.53 | $250,236 | +13.36% | ||
| 2026-05-18 | MILLER RICHARD A MD | President and CEO | 6,932 0.0081% | $12.04 | $83,453 | +5.90% | ||
| 2025-06-27 | Sale | Thompson Peter A. | 1.18M 1.6308% | $4.16 | $4.89M | +118.51% | ||
| 2025-06-27 | Sale | ORBIMED ADVISORS LLC | 1.18M 1.6308% | $4.16 | $4.89M | +118.51% | ||
| 2024-05-06 | MILLER RICHARD A MD | President and CEO | 577,634 1.0676% | $1.73 | $1,000,000 | +122.51% | ||
| 2024-05-06 | Jones William Benton | See Remarks | 20,000 0.037% | $1.73 | $34,624 | +122.51% | ||
| 2023-05-15 | Grais Linda | director | 10,000 0.0202% | $2.45 | $24,500 | -22.88% | ||
| 2022-12-20 | Jones William Benton | See Remarks | 20,000 0.0435% | $0.79 | $15,800 | +85.90% | ||
| 2022-12-14 | MILLER RICHARD A MD | President and CEO | 10,000 0.021% | $0.78 | $7,812 | +77.50% | ||
| 2022-12-14 | LEA LEIV | Chief Financial Officer | 4,000 0.009% | $0.84 | $3,364 | +77.50% | ||
| 2022-12-13 | MILLER RICHARD A MD | President and CEO | 50,000 0.1031% | $0.74 | $37,015 | +84.18% | ||
| 2022-12-13 | LEA LEIV | Chief Financial Officer | 30,000 0.0621% | $0.74 | $22,275 | +84.18% | ||
| 2022-06-24 | MILLER RICHARD A MD | President and CEO | 5,000 0.0123% | $1.00 | $4,985 | +4.60% | ||
| 2022-06-02 | MILLER RICHARD A MD | President and CEO | 890 0.002% | $1.01 | $899 | -7.89% | ||
| 2022-03-31 | MILLER RICHARD A MD | President and CEO | 15,000 0.0321% | $1.64 | $24,534 | -44.51% | ||
| 2022-03-16 | LEA LEIV | Chief Financial Officer | 13,878 0.0307% | $1.65 | $22,899 | -42.38% | ||
| 2022-03-15 | MILLER RICHARD A MD | President and CEO | 5,000 0.0117% | $1.59 | $7,950 | -36.44% | ||
| 2021-10-01 | Sale | EcoR1 Capital, LLC | 10 percent owner | 2M 4.4342% | $4.96 | $9.93M | -67.36% | |
| 2021-09-30 | Sale | EcoR1 Capital, LLC | 10 percent owner | 3M 6.7156% | $5.04 | $15.13M | -67.46% | |
| 2021-09-20 | Sale | Thompson Peter A. | 1.11M 2.4922% | $6.09 | $6.76M | -73.58% |
| MILLER RICHARD A MD | President and CEO | 1195035 1.4206% | $11.75M | 30 | 0 | +9.52% |
| Moore David Scott | director | 21700 0.0258% | $213,311.00 | 1 | 0 | |
| ORBIMED ADVISORS LLC | 7165006 8.5175% | $70.43M | 19 | 2 | +4.76% | |
| Thompson Peter A. | 7165006 8.5175% | $70.43M | 19 | 2 | +4.76% | |
| Novo Holdings A/S | 10 percent owner | 1389498 1.6518% | $13.66M | 3 | 5 | +12.06% |
| ADAMS STREET PARTNERS LLC | 10 percent owner | 236128 0.2807% | $2.32M | 2 | 0 | <0.0001% |
| Gould Terry P | 236128 0.2807% | $2.32M | 2 | 0 | <0.0001% | |
| Jones William Benton | See Remarks | 153773 0.1828% | $1.51M | 2 | 0 | +104.21% |
| LEA LEIV | Chief Financial Officer | 133238 0.1584% | $1.31M | 6 | 0 | +20.44% |
| Grais Linda | director | 10000 0.0119% | $98,300.00 | 1 | 0 | <0.0001% |
Corvus Pharmaceuticals, Inc. (CRVS) | $100,473,344 | 83 | 9.53% | $826.91M |
$5,911,307 | 70 | -1.38% | $884.8M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$11,663,618 | 57 | 32.20% | $934.29M | |
$59,156,363 | 22 | 29.25% | $686.5M |
| Increased Positions | 71 | +74.74% | 13M | +31.06% |
| Decreased Positions | 36 | -37.89% | 8M | -19.05% |
| New Positions | 30 | New | 6M | New |
| Sold Out Positions | 7 | Sold Out | 165,791 | Sold Out |
| Total Postitions | 130 | +36.84% | 47M | +12.01% |
| Orbimed Advisors Llc | $52,448.00 | 9.55% | 7.17M | 0 | 0% | 2025-09-30 |
| Point72 Asset Management, L.P. | $47,245.00 | 8.61% | 6.45M | -588,099 | -8.35% | 2025-09-30 |
| Blackrock, Inc. | $34,480.00 | 6.28% | 4.71M | +472,032 | +11.14% | 2025-09-30 |
| Vanguard Group Inc | $25,414.00 | 4.63% | 3.47M | +191,216 | +5.83% | 2025-09-30 |
| Adams Street Partners Llc | $23,978.00 | 4.37% | 3.28M | 0 | 0% | 2025-09-30 |
| Rtw Investments, Lp | $19,614.00 | 3.57% | 2.68M | 0 | 0% | 2025-09-30 |
| Vivo Capital, Llc | $16,357.00 | 2.98% | 2.23M | 0 | 0% | 2025-09-30 |
| Foresite Capital Management Vi Llc | $12,673.00 | 2.31% | 1.73M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $10,662.00 | 1.94% | 1.46M | +94,788 | +6.96% | 2025-09-30 |
| Perceptive Advisors Llc | $10,531.00 | 1.92% | 1.44M | 0 | 0% | 2025-09-30 |